Aurinia Pharmaceuticals Inc (AUPH)

From the record

Aurinia Pharmaceuticals Inc's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Aurinia Pharmaceuticals Inc's 8 filed years say what it did: revenue went from $463 thousand in fiscal 2018 to $283 million in fiscal 2025, up 150% a year; it rose in 5 of 7 years; the deepest fall was 31% from fiscal 2018 to fiscal 2019; net income was positive in 2 of 8 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Aurinia Pharmaceuticals Inc's diluted share count shrank about 0.8% a year, and dividends and buybacks returned about 94% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 2 sales and 11 purchases of their own stock on the open market in the year to 2026-09-30, buying about $25 million (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Aurinia Pharmaceuticals Inc earned about 49 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 33 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 23 cents per dollar of assets, and net share issuance: its share count shrank 5.1% over the year (the filed statements).

From the record

Aurinia Pharmaceuticals Inc's standing among 315 graded names in its industry family: revenue of $283 million in fiscal 2025 ranks in the top 24% by size; a net margin of 101.5% ranks in the top 3%; revenue growth of 28.3% a year over the last 3 filed years ranks in the top 32% (its annual reports).

From the record

Aurinia Pharmaceuticals Inc's leadership, from its insiders' filings and its current reports: the chief executive on the record is Tang, Kevin (Chief Executive Officer, as filed), filing under that title since 2026-06-02, 5 months (bottom 7% of its family); the 12 officers and directors filing in the last fifteen months have been on the record a median of 2.1 years (bottom 7%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 12 people in charge now (top 44%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Aurinia Pharmaceuticals Inc's room to grow, from the newest filed statements (fiscal 2025): cash of $80 million against no long-term debt tagged leaves 10.7% of its assets as net cash, bottom 27% of its family; cash from operations less capital spending is 47.9% of revenue (top 3%); a gross margin of 88.5% (top 19%); research spending of 11.5% of revenue (bottom 16%) (its annual report).

From the record

Aurinia Pharmaceuticals Inc's growth drivers, from the filed years to fiscal 2025: revenue grew 28.3% a year over the last three filed years against 150% over all 8, slowing (bottom 1% of its family); the newest year grew 20.4% (top 38%); research spending grew -10.3% a year (bottom 31%); capital spending grew 79.7% a year (top 12%) (its annual reports). Aurinia Pharmaceuticals Inc reported 2 product lines in fiscal 2025: Product at $271 million (96%), License Collaboration and Royalty Revenue at $12 million (4%); 1 of 2 grew against the year before (its annual report).

From the record

Aurinia Pharmaceuticals Inc's newest year against its own record: revenue of $283 million in fiscal 2025 came in 9.1% below the $311 million its prior three years' pace pointed to (bottom 40% of its family); net income of $287 million against a prior three-year average of $60 million (top 2%); a net margin of more than its whole revenue against -40.9% before (top 30%) (its annual reports).